合用氯米帕明对精神分裂症患者生存质量的影响  

The quality of life in long-term hospitalized schizophrenic patients treated with clomipamine-A comparative study

作　　者：王鹤秋[1] 于恩彦[2] 陈虹[1] 任志斌[1] 

机构地区：[1]浙江省立同德医院,杭州310012 [2]浙江医院

出　　处：《浙江医学》2005年第4期253-255,共3页Zhejiang Medical Journal

摘　　要：目的了解合用氯米帕明对长期住院的精神分裂症患者生存质量的影响。方法将120例精神分裂症患者分为合用组与对照组,合用组在对照组所用抗精神病药物基础上联合应用氯米帕明。采用阳性与阴性症状量表(PANSS)、健康状况问卷量表(SF-36)进行疗效和生存质量评估。结果治疗前两组PANSS评分为39.62±7.82和39.25±6.61,差别无显著性意义(P>0.05),治疗后为35.32±6.25和39.64±6.82,差别有显著性意义(P<0.01);治疗结束后合用组的生理机能、社会功能、情感职能3个因子分及生存质量总分均明显高于单用抗精神病药物组(均P<0.01),合用组上述4个指标以及生理职能方面治疗前后差别均有显著性意义(均P<0.01)。结论合用氯米帕明治疗长期住院的精神分裂症患者可提高其生存质量。Objective To observe the quality of life (QOL) in long-term hospitalized schizophrenic patients treated with clomipamine. Methods One hundred and twenty inpatients with schizophrenia were randomly divided into two groups: one group receiving clomipamine and another without clomipamine (control group). The treatment lasted for two months, then the positive and negative symptom scale(PANSS) and short Form 36 of Health survey Questionnaire (SF-36) were used to evaluate the effect and the quality of life. Results There was no significant difference in the positive scores of PANSS between two groups, but there was significant difference in the negative symptom scores and the total scale of PANSS between two groups. The physical functioning, social functioning, role-emotional factor scores and the total scores of SF-36 in clomipamine group were significantly higher than those in control group (P<0.01). There were also significant differences in these indexes in the clomipamine group before and after treatment. Conclusion Clomipamine may improve the quality of life for long-term hospitalized patients with schizophrenia.

关 键 词：精神分裂症患者 氯米帕明 阳性与阴性症状量表 生存质量评估 抗精神病药物 长期住院 NSS评分 显著性 药物基础 健康状况 生理机能 社会功能 治疗前后 对照组 差别 治疗后 因子分 职能 

分 类 号：R749.3[医药卫生—神经病学与精神病学] R971.4[医药卫生—临床医学]